Results 151 to 160 of about 124,797 (309)

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić   +4 more
wiley   +1 more source

Should the government provide insurance for catastrophes? [PDF]

open access: yes
This paper evaluates the need for a government role in insuring natural and man-made catastrophes in the United States. Although insurance markets have been stressed by major natural catastrophes, such as Hurricane Katrina, government involvement in the ...
J. David Cummins
core  

PERFORMANCES OF THE ROMANIAN INSURANCE MARKET [PDF]

open access: yesAnnals of the University of Petrosani: Economics, 2013
Global crisis affected the worldwide insurance market differently from one country to another, so Romanian insurance market in the period between 2008 and 2012 was also affected by global crisis. Effectiveness and performance of the insurance market from Romania is discussed in the paper based on the statistical data published by the Insurance ...
openaire   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Latvian Insurance Market Development as Member of the European Insurance and Reinsurance Federation

open access: yes
Having jointed into European Union in 2004 the 1st of May, Baltic States have become an integral part of insurance market. The idea of united insurance market establishment has 30 years history. The established viewpoint that the most important moment in
Baranovskis, Nikolajs, Polovko, Svetlana
core  

The Effectiveness of Insurance Fraud Statutues: Evidence from Automobile Insurance [PDF]

open access: yes
Insurance fraud, which adds an estimated $85 billion per year to the total insurance bill in the U.S., is an extremely serious problem for consumers, regulators, and insurance companies.
Lars S. Powell   +2 more
core  

Global trends in the insurance market and the functioning of the insurance market in Serbia

open access: yesStrategic Management, 2014
During 2010 , the insurance sector globally managed to overcome the effects of the economic crisis, with re-growth of insurance premiums especially in some economies, particularly in the life insurance sector, positive returns on investment, and certainly, associated with it, to strengthen the position of solvency.
openaire   +1 more source

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer   +4 more
wiley   +1 more source

LIBERALIZATION AND MARKET CONCENTRATION IN THE INSURANCE INDUSTRY: CASE OF CROATIA

open access: yesEconomic Review, 2011
This paper analyzes market concentration on the market of insurance companies in Croatia. For a very long time, Croatian insurance market was dominated by one company.
Lorena Škuflić   +2 more
doaj  

Home - About - Disclaimer - Privacy